<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473486</url>
  </required_header>
  <id_info>
    <org_study_id>2006-005970-26</org_study_id>
    <secondary_id>KKS / INNERE_A / NSCLC2006</secondary_id>
    <nct_id>NCT00473486</nct_id>
  </id_info>
  <brief_title>Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib</brief_title>
  <acronym>PECASO</acronym>
  <official_title>A Randomized (PhaseII), Double-blind, Multicenter Phase I/II Trial of Pemetrexed, Carboplatin Plus or Minus Sorafenib in the First-line Treatment of Patients With Stage IIIb or IV Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Muenster</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Muenster</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The majority of patients with advanced NSCLC treated with standard platinum based&#xD;
      chemotherapy regimens ultimately develop disease progression. Active therapies with improved&#xD;
      toxicity profiles are clearly needed in this setting. The primary objective of this trial is&#xD;
      to assess the toxicity profile and to determine the effect on progression free survival and&#xD;
      time to progression in patients with advanced NSCLC treated with sorafenib in addition to&#xD;
      carboplatin and pemetrexed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sorafenib administered in the combination with pemetrexed-carboplatin appears to enhance&#xD;
    thrombocytopenia compared to historical data.&#xD;
  </why_stopped>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ph.1: Identify the recommended phase II dose of sorafenib for combination therapy with carboplatin and pemetrexed</measure>
    <time_frame>July 2008</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ph.2: Compare the PFS of carboplatin/pemetrexed + sorafenib or carboplatin/pemetrexed + placebo in patients with stage IIIb or IV non-small cell lung cancer</measure>
    <time_frame>May 2009</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ph.1: Determine dose limiting toxicity</measure>
    <time_frame>July 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph 1: Determine the safety profile of the combination treatment</measure>
    <time_frame>July 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph 1: descriptive analysis of efficacy</measure>
    <time_frame>July 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph.2: Compare PFS of carboplatin/pemetrexed + sorafenib or carboplatin/pemetrexed + placebo in patients with stage IIIb or IV NSCLC</measure>
    <time_frame>May 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph 2: Assess time to progression in patients treated with either regimen</measure>
    <time_frame>May 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph 2: Determine the overall survival in patients treated with either regimen</measure>
    <time_frame>May 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph 2: Determine the objective response rate (CR, PR), disease control rate (CR,PR,SD), time to response and duration of response</measure>
    <time_frame>May 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph 2: Identify surrogate markers from the tumor biopsy or resection specimen from the time of diagnosis that predict response</measure>
    <time_frame>May 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph 2: Assess Quality of Life of patients treated with either regimen</measure>
    <time_frame>May 2009</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ph 2: Assess feasibility and toxicity profile of this regimen</measure>
    <time_frame>May 2009</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pemetrexed, Carboplatin plus Sorafenib in the first-line treatment of patients with stage IIIb or IV NSCLC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pemetrexed, Carboplatin plus placebo in the first-line treatment of patients with stage IIIb or IV NSCLC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed, carboplatin, sorafenib</intervention_name>
    <description>Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19&#xD;
Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pemetrexed, carboplatin, placebo</intervention_name>
    <description>Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed NSCLC&#xD;
&#xD;
          -  Locally advanced (stage IIIB with malignant pleural or pericardial effusion) or&#xD;
             metastatic (stage IV) NSCLC&#xD;
&#xD;
          -  No prior systemic chemotherapy&#xD;
&#xD;
          -  Prior local radiotherapy is allowed if it is completed at least 3 weeks prior to the&#xD;
             first dose of study medication; also concomitant palliative radiotherapy to an&#xD;
             existing bone lesion for pain control is allowed&#xD;
&#xD;
          -  Prior surgery is allowed if it is performed at least 4 weeks prior to the first dose&#xD;
             of study medication and patient should be fully recovered.&#xD;
&#xD;
          -  Must have measurable disease with at least one lesion with a longest diameter measured&#xD;
             as ≥ 2 cm with conventional techniques or as ≥ 1 cm with spiral CT&#xD;
&#xD;
          -  Age ≥18 years old&#xD;
&#xD;
          -  ECOG performance score (PS) 0-1&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Adequate bone marrow, renal and hepatic function&#xD;
&#xD;
               -  hemoglobin ≥ 9.0 g/dl&#xD;
&#xD;
               -  absolute neutrophil count ≥1,500/mm3&#xD;
&#xD;
               -  platelet count ≥ 100,000/mm3&#xD;
&#xD;
               -  total bilirubin ≤ 1.5 times the upper limit of normal&#xD;
&#xD;
               -  ALT and AST ≤ 2.5 times the upper limit of normal (≤ 5 x upper limit of normal&#xD;
                  for patients with liver involvement)&#xD;
&#xD;
               -  INR ≤ 1.5 and aPTT within normal limits&#xD;
&#xD;
               -  serum creatinine ≤ 1.5 the upper limit of normal&#xD;
&#xD;
          -  Patients with creatinine clearance ≥ 45 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing patients&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum pregnancy test performed&#xD;
             within 7 days prior to the start of treatment&#xD;
&#xD;
          -  Women of childbearing potential and men must agree to use adequate contraception&#xD;
             (barrier method of birth control) prior to study entry and for the duration of study&#xD;
             participation. Men should use adequate birth control for at least six months after the&#xD;
             last administration of sorafenib&#xD;
&#xD;
          -  Signed informed consent prior to any study specific procedures&#xD;
&#xD;
          -  Compliance and geographic proximity that allow adequate follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior systemic anticancer therapy including cytotoxic therapy, targeted agents,&#xD;
             experimental therapy (treatment within the last 30 days with a drug that has not&#xD;
             received regulatory approval for any indication at the time of study enrollment),&#xD;
             adjuvant, or neo-adjuvant therapy for NSCLC&#xD;
&#xD;
          -  Any participation in a clinical trial 30 days prior to study entry and concomitantly&#xD;
             to the study&#xD;
&#xD;
          -  Cardiac disease: Congestive heart failure &gt; class II NYHA. Patients must not have&#xD;
             unstable angina (angina symptoms at rest) or new-onset angina (began within the last 3&#xD;
             months) or myocardial infarction within the past 6 months&#xD;
&#xD;
          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy&#xD;
&#xD;
          -  Uncontrolled hypertension defined as systolic blood pressure &gt; 150 mm Hg or diastolic&#xD;
             pressure &gt; 90 mm Hg, despite optimal medical management&#xD;
&#xD;
          -  Documented brain metastases (unless the patient is &gt; 6 months from definitive therapy&#xD;
             for brain metastases, has a negative imaging study within 4 weeks of study entry and&#xD;
             has been off corticosteroids for at least 4 weeks before study enrolment). Brain&#xD;
             imaging (CT scan/MRI) is required in symptomatic patients to rule out brain&#xD;
             metastases, but is not required in asymptomatic patients.&#xD;
&#xD;
          -  Patients with seizure disorder requiring medication (such as steroids or&#xD;
             antiepileptics)&#xD;
&#xD;
          -  Known HIV infection or chronic hepatitis B or C&#xD;
&#xD;
          -  Active clinically serious infections &gt; CTCAE Grade 2&#xD;
&#xD;
          -  Presence of clinically significant third-space fluid collections, for example, ascites&#xD;
             or pleural effusions that cannot be controlled by drainage or other procedures prior&#xD;
             to study enrolment&#xD;
&#xD;
          -  Pulmonary hemorrhage/bleeding event &gt;= CTCAE Grade 2 within 4 weeks of first dose of&#xD;
             study drug&#xD;
&#xD;
          -  Any other hemorrhage/bleeding event &gt; =Grade 3 within 4 weeks of first dose of study&#xD;
             drug&#xD;
&#xD;
          -  Evidence or history of bleeding diathesis or coagulopathy&#xD;
&#xD;
          -  Therapeutic anticoagulation with vitamin K antagonists such as phenprocoumon,&#xD;
             warfarin, or with heparins or heparinoids. Low dose anticoagulation is permitted&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Major surgery, open biopsy or significant traumatic injury within 4 weeks of first&#xD;
             dose of study drug&#xD;
&#xD;
          -  Known or suspected allergy to sorafenib, carboplatin or pemetrexed&#xD;
&#xD;
          -  Previous or current cancer that is distinct in primary site or histology from NSCLC&#xD;
             except cervical cancer in-situ, treated basal cell carcinoma, superficial bladder&#xD;
             tumors (Ta and Tis) or any cancer curatively treated &gt; 3 years prior to study entry&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the patients participation in the study&#xD;
&#xD;
          -  Significant weight loss (&gt; or equal 10% body weight during preceeding 6 weeks)&#xD;
&#xD;
          -  Inability to interrupt aspirin or other nonsteroidal anti-inflammatory agents, other&#xD;
             than an aspirin dose ≤ 1.3 grams per day, for a 5-day period (8-day period for&#xD;
             long-acting agents, such as piroxicam)&#xD;
&#xD;
          -  Inability or unwillingness to take folic acid, vitamin B12 supplementation or&#xD;
             corticosteroids&#xD;
&#xD;
          -  Recent (within 30 days of enrolment) or concurrent yellow fever vaccination&#xD;
&#xD;
          -  Serious concomitant systemic disorder that, in the opinion of the investigator, would&#xD;
             compromise the patient's ability to adhere to the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Brandts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Münster, Med. Klinik und Poliklinik A, Hämatologie, Onkologie und Pneumologie and Uniklinik Frankfurt Innere Medizin, Hämatologie/Onkologie, 60590 Frankfurt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Muenster, Dept. of Medicine, Hematology / Oncology</name>
      <address>
        <city>Muenster</city>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2007</verification_date>
  <study_first_submitted>May 14, 2007</study_first_submitted>
  <study_first_submitted_qc>May 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2007</study_first_posted>
  <last_update_submitted>January 26, 2010</last_update_submitted>
  <last_update_submitted_qc>January 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Dr. Christian Brandts Principal Investigator</name_title>
    <organization>University Hospital Muenster and University Hospital of Frankfurt</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

